Armata Pharmaceuticals, Inc. · AMEX:ARMP
Armata Pharmaceuticals — IPO Roadshow (January 2020)
29 slides from Armata Pharmaceuticals's IPO roadshow presentation, Jan 9, 2020
Slide 1: Armata Pharmaceuticals Issuer Free Writing Prospectus, January 2020
Todd Patrick, Chief Executive Officer Brian Varnum, President and Chief Development Officer Steve Martin, Chief Financial Officer January 2020 NYSE American: ARMP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333 - 235656
Slide 2: Free Writing Prospectus Statement
2 I This presentation highlights basic information about us and the offering to which this communication relates . Because it is a summary, it does not contain all of the information that you should consider before investing in our securities . We have filed a registration statement (including a pro
Slide 3: Forward-looking statements
3 I This presentation contains “forward - looking” statements that involve risks, uncertainties and assumptions . If the risks or uncertainties materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward - looking statements . All
Slide 4: Offering Summary
4 I Offering Summary Ticker / Exchange ARMP (NYSE American) Type of Offering Follow - on Offering off of Form S - 1 Securities Offered Common stock Use of Proceeds To fund manufacturing expenses, research and development expenses including clinical development of our second - generation Pseudomonas
Slide 5: Investment Highlights: A Leader in Phage Therapeutics
5 I Two phage product candidates advanced through Pre - IND meeting with FDA • Expected IND filing for P. aeruginosa phage product candidate in 1H 2020 – Cystic fibrosis initial target indication • S. aureus phage product candidate IND expected in 2H 2020 – Bacteremia indication subject to third par
Slide 6: Armata Stands on Long History of Phage Development
6 I Armata Stands on Long History of Phage Development M&A Yields Leading Phage Company Biocontrol Ltd. Pre - IND S. aureus and P. aeruginosa phage SGI Asset Acquisition Synthetic phage platform ▪ Pseudomonas program ▪ Pharma partnered program GMP Facility 25 MDR Cases Under EIND Targeted Antimicrob
Slide 7: Armata's Capabilities and Operational Overview
7 I Armata’s Capabilities and Operational Overview Built for Product Development, Bench to Clinic Microbiology Phage Discovery Peptide Chemistry Leads Synthetic Biology Manufacturing & Quality Regulatory • Preclinical biology • Deep formulation expertise • Host cell engineering • Two targeted antimi
Slide 8: Pipeline
8 I Pipeline Phage libraries to address market expansion and new indications Pathogen / Indication Discovery Preclinical IND - Enabling CMC Phase 1b/2 Pseudomonas aeruginosa Cystic Fibrosis Lung Infections Staphylococcus aureus Bacteremia* Undisclosed Partnered AP - PA02 AP - SA02 * pending nondilut
Slide 9: Unmet Need in Antibiotic Resistant Infections
9 I Unmet Need in Antibiotic Resistant Infections Phages May Provide a Powerful Solution to an Urgent Public Health Threat Aug 2019 Xenleta (lefamulin)
Slide 10: Bacteriophages Infection Yields Progeny and Results in Bacterial Lysis
10 I Bacteriophages Infection Yields Progeny and Results in Bacterial Lysis Source: Prescott Harley Klein’s Microbiology, 7th Ed. • The most ubiquitous organisms on Earth • Natural predators of bacteria • Highly targeted • Prior history as therapeutic agent – Antibiotics displaced phage use • Drug -
Slide 11: Differentiating Attributes of Phage vs. Classic Antibiotics
11 I Highly specific bactericidal agents will not disrupt microbiome • Lowers risk of infection by Clostridium difficile and vancomycin - resistant enterococci No toxicities associated with chemical structures • Toxicities associated with antibiotics: kidney, bone marrow, hearing loss… Not an increm
Slide 12: Deadly Infections Successfully Treated With Phage
12 I Deadly Infections Successfully Treated With Phage Aortic Graft Pseudomonas Cystic Fibrosis Pseudomonas Cystic Fibrosis Pseudomonas Cystic Fibrosis NTM
Slide 13: Lead Indication: Pseudomonas aeruginosa Cystic Fibrosis Lung Infections
13 I Lead Indication Pseudomonas aeruginosa Cystic Fibrosis Lung Infections
Slide 14: Primary Clinical Inquiry: Cystic Fibrosis
14 I Primary Clinical Inquiry: Cystic Fibrosis • Chronic P. aeruginosa infections occur in 55% of CF patients by age 25 – Strongly associated with deteriorating lung function, frequent pulmonary exacerbations, increased mortality • Increased risk of death at 8 years in children with P. aeruginosa in
Slide 15: Integrated Approach Yields Robust Pseudomonas Phage Candidate
15 I In Vitro Killing Kinetics In Vivo Screening Manufacturing Feasibility Integrated Approach Yields Robust Pseud Phage Candidate surveillance Candidate Screening Initial phage pool Identify receptors Genomic analysis ID phage family Confirm lytic Prioritize on desired attributes: Broad host range
Slide 16: AP-PA02: Phage Product Tailored for Pa Respiratory Infections
16 I • Distinct phage families • Targets 4 different receptor classes • Cooperative/compatible • Broadly active against clinical isolates • Highly potent • Rapid test to drive early use in treatment paradigm • Highly sensitive, can identify colonized patients AP - PA02: Phage Product Tailored for Pa
Slide 17: AP-PA02: Product Development Status
17 I • cGMP laboratory designed for manufacturing and formulating sterile products – ISO - certified cleanrooms and closed system isolator – Registered with FDA; licensed by California Department of Public Health • Staffing – Independent Quality Unit – cGMP - trained manufacturing and facilities per
Slide 18: AP-PA02: Clinical Outline
18 I Near - term study Follow - on studies Future Opportunities AP - PA02: Clinical Outline Patient population: Medically stable chronically - infected CF patients Route of administration: Nebulized Goals: Safety and tolerability, pharmacokinetics, dose exploration Efficacy endpoints in CF populatio
Slide 19: Further Leveraging on Phage: Staphylococcus aureus Bacteremia
19 I Further Leveraging on Phage Staphylococcus aureus Bacteremia
Slide 20: AP-SA02: Phage Product Targeting S. aureus
20 I • Host range coverage of >90% across clinical isolates tested • Robust potency against drug - resistant isolates, including MRSA, VISA, VRSA • Penetrates pre - existing biofilms • Maintains activity in presence of current standard anti - staphylococcal therapy AP - SA02: Phage Product Targeting
Slide 21: AP-SA02: Product Development Status
21 I • Manufacturing processes demonstrated – Process development feasibility runs completed – Release specifications for intravenous dosing form in development • Production of clinical trial material anticipated 2H 2020 AP - SA02: Product Development Status GMP Manufacturing • Phase 1b/2 dose escal
Slide 22: Corporate Summary
22 I Corporate Summary
Slide 23: Significant Opportunity to Improve Clinical Outcomes
23 I Significant Opportunity to Improve Clinical Outcomes Annual cost of treating all antibiotic - resistant infections in the US: $21 - $34 billion 1 Pseudomonas aeruginosa ARMP candidate AP - PA02 Methicillin Resistant Staphylococcus aureus (MRSA) Bacteremia ARMP candidate AP - SA02 • 32,600 new c
Slide 24: Armata's Vision: Improvements Through Engineering
24 I • Phage libraries provide basis for engineering – Identifying genetic elements contributing to phenotype • Combining genetic elements for improved attributes – Expanded host range – Increased burst size • Expression of heterologous proteins – Improved bactericidal and biofilm activity Armata’s
Slide 25: Strong Global IP Position Through Pending and Issued Patents
25 I Strong Global IP Position Through Pending and Issued Patents 14 Patent Families, Long - Life Patents, Patents Granted in all Major Jurisdictions Expiration dates through 2039 Armata’s patents and applications cover: Therapeutic phage cocktails (Staphylococcus and Pseudomonas) and uses thereof S
Slide 26: Anticipated Topline Milestones 2020
26 I Pseudomonas phage product candidate, AP - PA02 • US IND filing, and initiation of first - in - human CF study upon clearance • Obtain topline data • Obtain nondilutive funding to partially support clinical studies Staphylococcus phage product, AP - SA02 • Obtain nondilutive funding to initiate
Slide 27: Leadership and Board of Directors
27 I Leadership and Board of Directors Diverse Public Company Drug Development Expertise Management Todd R. Patrick CEO Steve Martin CFO Brian Varnum President and CDO Duane Morris VP, Operations Heather Jones VP, Clinical Development Board of Directors Richard Bastiani Chair Joseph M. Patti Richard
Slide 28: Highlight Summary: A Leader in Phage Therapeutics
28 I Highlight Summary A Leader in Phage Therapeutics Two bacteriophage candidates in clinical development Natural phage discovery and synthetic biology yield robust pipeline Merck partnership to develop proprietary synthetic phage to target an undisclosed infectious disease agent Phage - specific G
Slide 29: Armata Pharmaceuticals
‘» ARMATA PHARMACEUTICALS PURPOSEFUL @ PRECISE ¢ POWERFUL